Remix Therapeutics – a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease – recently announced closing a $60 million financing led by The Column Group. The funding includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company), along with new investors WTT Investment, Willett Advisors, and others. These funds will support the clinical development of the company’s lead program, REM-422, and further advancement of an RNA processing targeted therapeutics pipeline.
Driven by its proprietary technology platform, Remix is utilizing the power of data analytics and machine learning, bespoke high-throughput screening technologies, and next generation chemistry to advance a pipeline of breakthrough therapies designed to precisely modulate RNA processing. And the company’s innovative approach has the unique ability to identify and target RNA processing steps to degrade mRNA, enhance RNA production, or to correct RNA dysregulation in disease. Remix’s lead candidate REM-422 is expected to enter two Phase 1 clinical studies for the treatment of recurrent or metastatic adenoid cystic carcinoma and acute myeloid leukemia/myelodysplastic syndromes this year.
KEY QUOTES:
“We are proud of and encouraged by the support of such a strong syndicate of investors who believe in Remix’s ability to develop novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. This financing enables us to continue development of our pipeline and advance our lead program, REM-422, into the clinic for the treatment of adenoid cystic carcinoma and acute myeloid leukemia/myelodysplastic syndromes this year.”
— Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics
“Remix has made significant progress over the last several years, demonstrating pre-clinical proof-of-concept for several RNA processing programs discovered using its novel platform. We look forward to Remix realizing the full potential of its unique approach, advancing small molecules that can control gene expression to effectively treat a broad range of diseases.”
— Peter Svennilson, Founder and Managing Partner of The Column Group
